Arecor Therapeutics PLC · LSX:A3CRY2

Arecor Therapeutics PLC financial statements

Arecor Therapeutics PLC's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in GBP

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018
Revenue1.71M5.05M4.57M2.40M1.16M1.70M1.89M747.7K1.35M
Cost of revenue663.0K3.51M3.32M341.0K
Gross profit1.05M1.54M4.57M2.40M1.16M1.70M1.89M747.7K1.35M
Research and development2.69M3.04M5.98M8.61M5.39M3.94M3.56M3.09M2.33M
Selling, general and administrative3.17M6.18M8.91M5.55M2.39M1.64M1.61M1.42M1.00M
Operating income-4.67M-10.7M-9.18M-11.7M-5.98M-3.43M-2.69M-2.85M-1.40M
Depreciation and amortization215.0K446.0K496.0K341.0K171.0K168.0K151.5K166.9K172.9K
EBITDA-4.45M-10.3M-8.68M-11.3M-5.81M-3.26M-2.54M-2.69M-1.22M
Interest expense11.0K22.0K15.0K21.0K507.0K87.0K3.66K24.0K28.7K
Income before tax994.0K-10.6M-8.90M-10.5M-6.95M-3.51M-2.69M-2.87M-1.43M
Income tax62.0K-382.0K-347.0K-1.28M-776.0K-760.0K-502.3K-435.1K-307.0K
Net income664.0K-10.2M-8.55M-9.26M-6.17M-2.75M-2.19M-2.44M-1.12M
Earnings per share, basic0.02-0.31-0.28-0.32-0.27-0.10-0.08-0.09-0.04

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018FY2017
Cash and equivalents3.00M3.24M5.09M4.76M18.3M2.90M3.07M3.45M704.9K1.03M
Short-term investments3.13M18.0K1.66M8.04M
Receivables868.0K2.87M2.87M664.0K795.0K102.0K497.3K753.0K402.0K739.7K
Inventory0478.0K771.0K1.13M0-2071011.4K
Current assets7.00M8.23M11.2M17.5M20.5M3.82M3.92M5.00M1.52M1.90M
Property, plant and equipment838.0K328.0K375.3K295.1K353.1K438.5K551.7K
Goodwill01.48M1.48M0
Total assets8.10M8.72M15.4M21.8M20.9M4.28M4.31M5.45M2.07M2.56M
Accounts payable1.42M838.0K2.25M1.71M518.0K465.0K365.6K568.0K164.8K100.5K
Current liabilities1.61M3.26M5.15M3.73M2.27M1.41M1.04M1.11M823.3K958.6K
Long-term debt01.70M0351.8K
Total debt98.0K232.0K338.0K288.0K231.0K2.00M158.1K221.3K660.1K576.1K
Total liabilities1.65M3.37M5.85M4.31M2.37M3.51M1.10M1.23M1.40M1.23M
Shareholders' equity6.45M5.35M9.53M17.5M18.5M773.8K3.21M4.22M670.3K1.33M
Shares outstanding39.4M33.4M30.6M28.9M23.0M27.7M27.7M27.7M27.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018
Cash from operations-2.29M-9.15M-5.84M-10.8M-5.45M-1.86M-458.8K-2.50M-492.6K
Capital spending-99.0K-23.0K-151.0K-345.0K-69.0K-52.3K-32.3K-73.1K-12.9K
Free cash flow-2.39M-9.18M-5.99M-11.1M-5.52M-1.91M-491.1K-2.58M-505.5K
Cash from investing2.38M1.72M6.52M-7.99M-68.0K-49.3K-22.9K-64.6K-12.8K
Cash from financing-148.0K5.65M-180.0K5.16M20.9M1.77M-131.0K5.32M216.7K
Share buybacks4201.09K200.0K
Change in cash-238.0K-1.85M328.0K-13.6M15.4M-175.2K2.74M2.74M-323.4K